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Abstract: Econazole nitrate (ECN) is a weakly basic drug with very low 
aqueous solubility that hampers its permeation through biological 
membranes and results in low ECN bioavailability. Formation of 
drug/cyclodextrin (drug/CD) inclusion complexes is a formulation 
technology that can be applied to enhance drug solubility in aqueous 
media. The aim of this study was to determine the effect of CD 
complexation and pH adjustments on the ECN solubility. The ECN pH-
solubility and ECN/CD phase-solubility profiles were determined. The 
solubility of ECN in aqueous acidic solutions containing α-cyclodextrin
(αCD) was relatively high and much higher than in aqueous γ-cyclodextrin
(γCD) solutions under same conditions. The complexation efficiency of the
ECN/CD complex was relatively low for the unionized drug. Formation of 
ECN/CD inclusion complex was verified by proton nuclear magnetic 
resonance spectroscopy. Formation of ECN/CD complexes enhanced the drug 
stability during autoclaving. γCD complexes self-assembled to form nano- 
and microparticles whereas αCD complexes had negligible tendency to self-
assemble. Formation of CD complex nano- and microparticles was 
investigated by dynamic light scattering and by drug permeation through 
semipermeable membranes of different molecular weight cut-off. The 
largest aggregate fraction was observed for the unionized ECN in aqueous 
pH 7.5 solution containing high CD concentration, that is 10% (w/v) CD. 
It was shown that in acidic solutions ECN/αCD can enhance the antifungal
activity to filamentous fungi. This was associated with the increased ECN 
solubility and increase of readily available ECN molecules in aqueous αCD
solutions. 
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Abstract 17 
Econazole nitrate (ECN) is a weakly basic drug with very low aqueous 18 
solubility that hampers its permeation through biological membranes and results in 19 
low ECN bioavailability. Formation of drug/cyclodextrin (drug/CD) inclusion 20 
complexes is a formulation technology that can be applied to enhance drug solubility 21 
in aqueous media. The aim of this study was to determine the effect of CD 22 
complexation and pH adjustments on the ECN solubility. The ECN pH-solubility and 23 
ECN/CD phase-solubility profiles were determined. The solubility of ECN in aqueous 24 
acidic solutions containing α-cyclodextrin (αCD) was relatively high and much higher 25 
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than in aqueous γ-cyclodextrin (γCD) solutions under same conditions. The 26 
complexation efficiency of the ECN/CD complex was relatively low for the unionized 27 
drug. Formation of ECN/CD inclusion complex was verified by proton nuclear 28 
magnetic resonance spectroscopy. Formation of ECN/CD complexes enhanced the 29 
drug stability during autoclaving. γCD complexes self-assembled to form nano- and 30 
microparticles whereas αCD complexes had negligible tendency to self-assemble. 31 
Formation of CD complex nano- and microparticles was investigated by dynamic 32 
light scattering and by drug permeation through semipermeable membranes of 33 
different molecular weight cut-off. The largest aggregate fraction was observed for 34 
the unionized ECN in aqueous pH 7.5 solution containing high CD concentration, 35 
that is 10% (w/v) CD. It was shown that in acidic solutions ECN/αCD can enhance 36 
the antifungal activity to filamentous fungi. This was associated with the increased 37 
















1. Introduction 52 
 53 
Various pharmaceutical techniques can be applied to enhance solubility and 54 
permeability of poorly water-soluble drugs, such as pH adjustments, use of 55 
cosolvents, size reduction (e.g. micronization), complexation and formation of solid 56 
dispersions (Kawabata et al., 2011; Khadka et al., 2014). One of the more promising 57 
technologies is drug - cyclodextrin (CD) complexation. CDs are cyclic 58 
oligosaccharides consisting of D-D-glucopyranose units with hydrophilic outer 59 
surface and somewhat lipophilic central cavity. They increase the aqueous solubility 60 
of hydrophobic drugs through formation of water-soluble inclusion complexes. In 61 
general, uncharged hydrophobic molecules or their moieties, that is molecules that 62 
generally have poor aqueous solubility, have affinity for the CD cavity (Brewster and 63 
Loftsson, 2007; Jansook et al., 2018).  64 
Saturated aqueous drug/CD complex solutions frequently contain mixtures of 65 
inclusion and non-inclusion complexes (Loftsson et al., 2004). Both the natural CDs 66 
and their derivatives form CD aggregates. The diameter of the parent CD aggregates 67 
(i.e. of αCD, βCD and γCD) have been reported to be between about 200 and 300 68 
nm by dynamic light scattering (DLS) (González-Gaitano et al., 2002). Various 69 
analytical techniques, such as DLS, nuclear magnetic resonance (NMR) 70 
spectroscopy, transmission electron microscopy (TEM) and permeation through 71 
different molecular weight cut-off (MWCO) semipermeable membranes, are 72 
commonly used to detect and characterize the aggregates (Duan et al., 2005; 73 
Jansook et al., 2010a; Messner et al., 2010; Witte and Hoffmann, 1996).  74 
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Econazole nitrate (ECN) is an imidazole antifungal drug. Its antifungal activity 75 
appears to be associated with disruption of cell membranes (Dyas and Delargy, 76 
1994). Less than 1% of applied dose is absorbed into the general blood circulation 77 
after topical administration and, thus, currently ECN is mainly used to treat skin 78 
infections (Heel et al., 1978; Kalus, 2017). The low aqueous solubility of ECN (<1 79 
mg/ml at 20ºC) limits ECN permeation through biological membranes and results in, 80 
for example, low oral bioavailability (Al-Marzouqi et al., 2009; Dyas and Delargy, 81 
1994). Among natural CDs, αCD has the highest solubilizing effect on ECN whereas 82 
γCD has almost negligible effect (Díaz-Tomé et al., 2018; Mura et al., 1999). Various 83 
methods to enhance the complexing efficacy (CE) have been reviewed (Loftsson 84 
and Brewster, 2012; Loftsson and Duchêne, 2007). For example, ternary drug/CD 85 
complexes with hydroxyl-acids as third component enhanced ECN solubility with 86 
consequent improved drug dissolution (Jug et al., 2014; Mura et al., 2001; Mura et 87 
al., 1999). The entrapment of ECN in chitosan/SBEβCD nanoparticles provided 88 
mucoadhesive effect and sustained antifungal activity (Mahmoud et al., 2011). 89 
However, pH adjustments or drug ionization that increases the drug solubility can 90 
result in enhanced CE of ECN/CD complex. The aim of this study was to determine 91 
the effect of pH on the CD solubilization of ECN and thermal stability of ECN, and to 92 
investigate the influence of pH on formation of ECN/CD complex aggregates. The 93 
antifungal activity of the ECN/CD complexes was also evaluated. 94 
 95 
2. Materials and methods 96 
2.1 Materials 97 
Econazole nitrate (ECN) was purchased from Fagron Group (Amsterdam, 98 
Netherlands). α-Cyclodextrin (αCD) and γ-cyclodextrin (γCD) were purchased from 99 
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Wacker Chemie (Burghausen, Germany), and semi-permeable cellophane 100 
membranes (SpectaPor®, molecular weight cut-off (MWCO) 3500, 6-8000 and 12-101 
14000 Da) from Spectrum Europe (Breda, Netherlands). All other chemicals used 102 
were of analytical reagent grade purity. Milli-Q (Millipore, USA) water was used for 103 
preparation of all solutions. 104 
 105 
2.2 pH solubility profiles 106 
Excess amount of ECN was added to the unbuffered aqueous pH medium 107 
(pH from 2 to 9) without and with CD (5% w/v αCD or γCD). This pH range covered 108 
the ionized and unionized forms of ECN molecules. The desired pH was obtained by 109 
dropwise titration of the medium with concentrated aqueous sodium hydroxide or 110 
hydrochloric acid solutions. The suspension formed was agitated at room 111 
temperature (22-23qC) for 7 days and the pH was readjusted, if necessary. After 112 
equilibration the samples were removed and filtered through 0.45 Pm nylon 113 
membrane filter. Finally, the filtrate was diluted with a mixture of acetonitrile and 114 
water (30:70 v/v) and the amount of dissolved drug determined by a high-115 
performance liquid chromatographic (HPLC) method. 116 
 117 
2.3 Thermal stability of econazole 118 
The stability of ECN in aqueous solutions containing 5% (w/v) αCD or γCD, as 119 
well as in purified water, was determined by heating in an autoclave (Loftsson et al., 120 
2005). Heating of an aqueous drug suspension can promote complex formation and 121 
enhance the complexation efficiency (CE) (Loftsson and Brewster, 2012). Excess 122 
amount of ECN was dissolved in the aqueous complexation media and the pH 123 
adjusted with concentrated hydrochloric acid or sodium hydroxide to 3.0, 5.0 or 7.5. 124 
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The samples were equilibrated at 22-23°C for 24 h under constant agitation. The 125 
supernatant was filtered through 0.45 µm nylon membrane filter. The clear filtrate 126 
was then divided into three sealed vials that were heated in an autoclave for one, 127 
two and three heating cycles, each cycle consisted of heating to 121qC for 20 min. 128 
Then the ECN concentration in the vials was determined by HPLC. 129 
 130 
2.4 Solubility determinations 131 
Excess amount of ECN was added to aqueous solutions containing from 0 to 132 
12% (w/v) αCD or 0 to 15% (w/v) γCD. The pH of the saturated drug suspensions 133 
formed was adjusted with concentrated hydrochloric acid and sodium hydroxide to 134 
3.0±0.2, 5.0±0.2 or 7.5±0.2 and then heated in an autoclave (121°C for 20 min) 135 
followed by cooling to room temperature (Loftsson et al., 2005). Then a small 136 
amount of solid drug was added to the suspensions to promote drug precipitation. 137 
The suspensions were equilibrated at 22-23°C for 7 days under constant agitation. 138 
The pH was monitored and readjusted if necessary. After equilibrium was attained, 139 
the suspensions were filtered through 0.45 µm syringe filter, the filtrates were diluted 140 
with mixture of acetonitrile and water (70:30 v/v) and analyzed by HPLC. The 141 
determinations were done in triplicate. The apparent stability constants for the 142 
ECN/CD complexes (K1:1 and/or K1:2), the CE and the ECN:CD molar ratio were 143 
determined by Eqs.1-3 (Loftsson et al., 2007).  144 
 145 
              
       
        
                                                                                   Eq. 1 146 
 147 




                       
  
                                                                                  Eq. 3 150 
 151 
where S0 is the ECN solubility in the aqueous complexation media when no CD is 152 
present, St is the total amount of dissolved ECN, slope means the corresponding 153 
slope of the phase-solubility diagrams, K1:1 and K1:2 are the stability constants of the 154 
1:1 and 1:2 inclusion complexes. 155 
2.5 Quantitative determinations 156 
2.5.1 Econazole analysis  157 
ECN content analysis was performed on an ultra HPLC (UHPLC) component 158 
system Ultimate 3000 Series from Dionex Softron GmbH (Germering, Germany) 159 
consisting of a DGP-3600A pump with a degasser, WPS-3000TLS well plate 160 
sampler, TCC-3100 column compartment, photodiode array detector with 161 
Chromeloen software version 7.2.8 and Phenomenex Luna C18(2) 5 µm column 162 
(4.6x150 mm) with C18 security guard cartridge. The HPLC condition was as follows: 163 
Mobile phase:  50 mM aqueous ammonium acetate:acetronitrile 164 
(35:65% v/v) 165 
Flow rate:  1.0 ml/min 166 
Oven temperature:  ambient 167 
UV detector wavelength:  220 nm 168 
Injection volume:  20 µl  169 
ECN retention:  6 min 170 
 171 
2.5.2 αCD and γCD analysis  172 
Quantitative determinations of αCD and γCD in the samples obtained from 173 
phase solubility studies were performed on a reverse-phase UHPLC. Ultimate 3000 174 
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series system from Dionex Softron GmbH (Germering, Germany) consisting of LPG-175 
3400SD pump with a degasser, a WPS-3000 autosampler, a TCC-3100 column 176 
compartment operated at 30qC, and a CoronaTM ultraRSTM CAD. Phenomenex Luna 177 
C18 (150x4.60 mm) 5 Pm column with Security Guard (Phenomenex, Cheshire, UK) 178 
were used. Chromeleon™, version 7.2 SR4 chromatography data system (CDS) 179 
software (ThermoScientific) was used to analysis. The mobile phase consisted of 180 
acetonitrile and water (25:75 %v/v), the flow rate was 1.0 ml/min, and the injection 181 
volume was 10 Pl. 182 
 183 
2.6 1H-NMR spectroscopy 184 
Solutions of the pure compounds (i.e. ECN, αCD, γCD) and the CD 185 
complexes of 1:1 stoichiometry ( i.e., ECN/αCD and ECN/γCD) were prepared by 186 
dissolving in DMSO-d6:D2O (90:10 v/v) and equilibrated at 22-23°C under constant 187 
agitation for 24 h. Their spectrum and chemical shift values were recorded by using 188 
a 400 MHz 1H-NMR spectrometer (BRUKERTM model AVANCE III HD, Brucker 189 
Biospin GmbH, Karlsruhe, Germany). The resonance at 2.5000 ppm, due to residual 190 
solvent (DMSO-d6), was used as internal reference. 1H-NMR chemical shift change 191 
(∆δ) was calculated as ∆δ = δcomplex - δfree. 192 
 193 
2.7 Determinations of ECN/CD complexes aggregates  194 
2.7.1 Dynamic light scattering (DLS) measurement 195 
The particle size of ECN/CD based aggregates in solution was measured by 196 
DLS technique using Nanotrac Wave particle size analyzer (Microtrac Inc., 197 
Philadelphia, PA). The samples, that is ECN saturated aqueous αCD or γCD 198 
solutions (CD conc. 1, 5 and 10% w/v) of various pH, were placed in the cell holder. 199 
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The wavelength of the laser beam was set at 780 nm with the scattering angle of 200 
180o. The particle size and percentage of volume were recorded. Each 201 
measurement was conducted at 25 ± 0.5°C and carried out in triplicate. The mass 202 
distribution was calculated, assuming that the particle of the complexes and complex 203 





 𝐴𝑖  𝑅𝑖
𝑎 x100                                                                                                  Eq. 4 206 
 207 
where Mi is the mass distribution percentage, Ai is the intensity area, Ri is the 208 
hydrodynamic radius of the size population i and a is the shape parameter which 209 
equals to 3, assuming the spherical particles (Bonini et al., 2006; González-Gaitano 210 
et al., 2002).  211 
 212 
2.7.2 Permeation studies 213 
To investigate the effect of pH and CD concentration on the size of ECN/CD 214 
complex aggregates, the in vitro ECN permeation from ECN saturated 1, 5 and 10% 215 
(w/v) αCD and γCD solutions at pH of 3, 5 and 7.5 through semi-permeable 216 
membranes was studied in a Franz diffusion cell apparatus consisting of a donor 217 
compartment and a receptor compartment (12 ml). The donor and receptor 218 
compartments were separated by the semi-permeable membrane with MWCO 3500, 219 
6-8000 or 12–14,000 Da. The receptor phase consists of 2.5% (w/v) αCD or γCD in 220 
pure water. CD was added in the receptor phase to allow for sink condition. Two 221 
milliliters of each sample were placed in the donor compartment. The receptor phase 222 
was kept at ambient temperature (22-23°C) and stirred continuously (300 rpm) 223 
during the experiment. A 150-µl aliquot of the receptor medium was withdrawn at 1, 224 
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2, 3, 4 and 6 h for analysis and replaced immediately by an equal volume of fresh 225 
receptor medium. The ECN content was determined by HPLC and the amount of 226 
drug permeation was calculated. Each sample was done in triplicate. The steady 227 
state flux (J) was calculated as the slope of linear plots of the amount of drug in the 228 
receptor chamber (q) versus time and the apparent permeation coefficient (Papp) 229 




 𝑃𝑎𝑝𝑝 𝐶𝑑                                                                                                 Eq. 5 232 
 233 
where A is the surface area of the mounted membrane (1.77 cm2) and Cd is the 234 
concentration of dissolved drug in the donor chamber. 235 
 236 
2.8 Antifungal susceptibility test 237 
The methods for antifungal susceptibility testing were modified according to 238 
Clinical and Laboratory Standards Institute (CLSI), formerly the National Committee 239 
for Clinical Laboratory Standards (NCCLS) document M27-A3 and M38-A2 of yeasts 240 
and filamentous fungi, respectively (CLSI, 2008a; 2008b). Three isolates fungal 241 
organisms i.e., Candida albicans (DMST 15317), Aspergillus flavus (13-56-29897) 242 
and Fusarium solani (13-61-03470) were tested by broth microdilution assay. Briefly, 243 
the isolated organisms were subcultured onto sabouraud dextrose agar (SDA) slants 244 
and stored as suspensions at 2-8 qC. The suspensions of tested organisms were 245 
diluted with 0.85% saline to the density of 1x106 - 5x106 cells/ml. The turbidity of the 246 
supernatant was determined by UV-VIS spectroscopy (Model UV-1601, Shimadzu, 247 
Japan) at a wavelength of 530 nm. The tests were conducted in 96-well culture 248 
plates. Each well was inoculated with 50 μl of two-fold dilution inoculum suspension. 249 
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An aliquot of 50 μl of test samples was placed in separate wells in triplicate after 250 
appropriate dilution with the tested media. DMSO and the ECN-free medium were 251 
included as growth control. The plates were incubated at 35 qC for 24 h (C. albicans) 252 
and for 96-120 h (A. flavus and F. solani).  253 
Minimum inhibitory concentrations (MICs) were read and defined as the 254 
lowest ECN concentration at which no growth could be observed. After MIC 255 
readings, 10 Pl aliquots were removed from each growth-negative well and were 256 
spread on SDA petri dishes. The plates were incubated in 35qC, and the fungal 257 
colonies grown were counted after 2 days and approximately 4-7 days of incubation 258 
for yeast and filamentous fungi, respectively. The minimum fungicidal concentrations 259 
(MFCs) were defined as the lowest drug concentration from which no colonies were 260 
visible on the agar plate. 261 
 262 
3. Results and discussion 263 
 264 
3.1 pH solubility profiles 265 
The pH solubility profiles of ECN in aqueous solutions without and with CD 266 
(5% w/v αCD or γCD) are shown in Fig. 1. The desired pH of the aqueous solutions 267 
was adjusted with diluted hydrochloric acid or sodium hydroxide. The aqueous 268 
solubility of ECN is less than 1 mg/ml (Abd El-Gawad et al., 2017; Pedersen et al., 269 
1993). ECN has pKa of 6.6. At pH ranging from 2 to 5, ECN molecules are 270 
protonated and somewhat soluble in water. In contrast, at pH above 7.5 the ECN 271 
molecules are mainly in their unionized form and very poorly soluble in water (Fig. 2). 272 
Addition of CD increases the ECN solubility. αCD is a better solubilizer of ECN than 273 
γCD. ECN had affinity to αCD resulting in significantly enhanced ECN solubility 274 
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through formation of water-soluble ECN/αCD complex. It has been reported that αCD 275 
is the best CD solubilizer for ECN of all CDs tested (Díaz-Tomé et al., 2018; Mura et 276 
al., 2001). To evaluate the effect of pH on CD complexation with ECN, the pH of 277 
solutions i.e., 3.0, 5.0 and 7.5 were selected for further studies. Of these the pH, 278 
ECN molecules exhibit fully ionized, partially ionized and unionized forms, 279 
respectively.  280 
 281 
3.2 Thermal stability of econazole on cycles of autoclaving 282 
 283 
 The thermal stability of ECN in aqueous solutions without and with CD (αCD 284 
or γCD, 5% w/v) at the pH 3, 5 and 7.5 was determined by heating in an autoclave 285 
(each heating cycle: 121oC for 20 min). Table 1 shows the drug remaining in the 286 
complexation media after zero to three cycles of autoclaving. The drug content at pH 287 
3 with and without CD did not decrease upon heating for up to 3 cycles. At pH 5, the 288 
drug concentration in pure water or aqueous solution containing 5% w/v γCD 289 
decreased after heating for 2 cycles while it was stable in aqueous solutions 290 
containing αCD. However, upon increasing the pH to 7.5 the drug degraded rapidly 291 
in the αCD solution or from 5% to 18% after 1 to 3 cycles of autoclaving. The ECN 292 
content after heating for 3 cycles was significantly decreased when compared to that 293 
of no autoclaving (P<0.05). The protonated drug is thermally stable while the 294 
unionized drug is somewhat unstable. The degradation products of ECN would be 295 
produced by hydrolysis of the ether linkage in parent ECN molecule (Dyas and 296 
Delargy, 1994). Baker et al. (2016) have found the degradation product of ECN after 297 
heating with 5% hydrogen peroxide at 90 °C for 2 h. CD can insulate labile 298 
compounds from the environment to prevent drug hydrolysis and oxidation; for 299 
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examples, doxorubicin, aspirin and β-lactam antibiotics (Loftsson and Brewster, 300 
1996; Popielec et al., 2016). The stabilizing effect of CD depends on the type and 301 
concentration of CD, the degree of the complex formation and the rate of 302 
degradation within the complex (Loftsson et al., 2005). In this case, addition of αCD 303 
may shield the ECN molecules by encapsulating them against the hydrolysis 304 
degradation process.  305 
 306 
3.3 Solubility determinations 307 
The phase solubility diagrams of ECN in αCD solutions were of type A (Fig. 308 
3a) while their diagrams in γCD solutions were of Bs-type (Fig. 3b) according to 309 
Higuchi-Connor classification system (Higuchi and Connors, 1965). At the pH lower 310 
than the pKa value (i.e., pH 3.0 and 5.0), the ECN/αCD phase solubility diagram is of 311 
AN-type. However, the stoichiometry of the ECN/αCD complex formed is 1:1.  In 312 
other words, one ECN molecule forms a complex with one αCD molecule. At pH 313 
higher than the pKa, the unionized form of ECN forms second or higher order 314 
complexes with αCD and AP-type phase solubility diagram is observed. In case of 315 
γCD, the drug solubility was increased with increasing γCD concentration with a 316 
maximum solubility at 3% (w/v) γCD at pH 3 and 1% w/v γCD at pH 5, with a 317 
following decreased solubility at higher γCD concentrations. It indicates that the ECN 318 
forms complexes and complex aggregates with γCD which have limited solubility in 319 
aqueous solutions. At pH 7.5 the solubility of the ECN/γCD complex was below the 320 
limit of quantitation (LOQ). Table 2 shows the apparent stability constants (K1:1 and 321 
K1:2), the complexation efficiency (CE) which was calculated from the slopes of the 322 
initial linear sections of the diagrams, and the molar ratio (ECN:CD). The determined 323 
intrinsic solubilities of ECN at the pH of 3 were 10 and 1000 times higher than at pH 324 
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of 5 and 7.5, respectively. ECN is a weak base and, thus the protonized form is 325 
somewhat more soluble in water than the unionized form.  Regarding to apparent 326 
stability constant (K), ECN had stronger binding affinity to αCD. The strong 327 
association is probably due to fit of ECN molecule into CD cavity. The number of 328 
αCD and γCD molecules needed to solubilize one ECN molecule (i.e. the molar 329 
ratio) was calculated from the CE values. The commercial 1% (w/w) econazole 330 
cream contains 10 mg of econazole nitrate per one gram. The results show that it is 331 
possible to develop aqueous econazole hydrogel containing CD at low pH (pH 3 or 332 
5) by including 80-100 mg of αCD or 140-280 mg of γCD per one gram hydrogel but 333 
at pH 7.5 about 550 mg αCD/gram will be needed to solubilize ECN which is not 334 
practical. 335 
 336 
3.4 Quantitative analysis of αCD and γCD  337 
The presence of ECN decreased the aqueous solubility of γCD while ECN 338 
has negligible effect on the αCD solubility (Fig. 4). According to the phase-solubility 339 
profiles, precipitation of the ECN/γCD complexes resulted in limited ECN solubility at 340 
elevated γCD concentrations. If formation of 1:1 ECN/γCD complex is assumed, the 341 
number of γCD molecules in the saturated aqueous ECN solutions should be 342 
proportional to the ECN solubility profiles. However, it was found that the observed 343 
γCD solubility did slightly deviated from the theoretical values (Fig. 4b). This might 344 
indicate that γCD self-aggregates at elevated γCD concentrations. This self-345 
aggregation strongly affected the ECN solubility. The observations were in 346 
accordance with previous reports (Jansook et al., 2010b; Messner et al., 2011). The 347 
media pH did not have any significant effect on the CD solubility in saturated ECN 348 




3.5 1H-NMR analysis 351 
1H-NMR chemical shifts of αCD and γCD are summarized in Table 3. The H3 352 
and H5 protons of the glucose units are facing the interior of the lipophilic CD cavity. 353 
The changes in 1H-chemical shifts (Δδ) of the H3 proton of αCD and γCD in the 354 
presence of ECN were -0.176 and -0.064, respectively, displaying significant upfield 355 
shift, while the H5 proton of both CDs exhibited insignificant chemical shift (i.e. 356 
+0.028 and -0.027 for αCD and γCD, respectively). The Δδ* of the H3 proton was 357 
higher than that of the H5 proton indicating the partial inclusion of ECN into the CD 358 
cavity (Greatbanks and Pickford, 1987). In comparison, the lipophilic moiety of ECN 359 
was more efficiently inserted into αCD cavity than into that of γCD. This observation 360 
supported the obtained phase solubility data and the fact that αCD is better 361 
solubilizer of ECN than γCD. The results are consistent with the 1D and 2D NMR 362 
data obtained by Díaz-Tomé et al. (Díaz-Tomé et al., 2018). They suggested that the 363 
imidazole ring of ECN was included into the CD cavity.  364 
 365 
3.6 Determinations of ECN/CD complexes aggregates 366 
Table 4 shows the size and size distribution data of ECN/CD complexes in 367 
aqueous solutions at different pH. The particle size distributions varied, ranging from 368 
mono-, bi- to trimodal distribution. In most cases, no complex aggregates were seen 369 
in the saturated ECN aqueous solutions containing 1% w/v CD. In most cases, small 370 
and large aggregates were observed when the CD concentration was increased to 371 
5% and 10% w/v. The influence of pH on the ECN/CD complex aggregation was also 372 
examined. It was noticed that the aggregate size and the size distribution increased 373 
with increasing pH. This was probably due to ECN protonation at low pH and the 374 
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consequent charge-charge repulsion. Especially, at the pH 3 there was insignificant 375 
difference among CD concentrations in the tendency to form aggregates. In other 376 
words, the unionized ECN/CD complex present at high pH has greater tendency to 377 
self-association to form complex aggregates than complexes of the ionized drug. 378 
Permeation of drug through semi-permeable membranes of different MWCO 379 
can be used to observe aggregation of drug/CD complexes (Messner et al., 2010). 380 
According to the phase solubility profiles, the stoichiometry of ECN/CD complex can 381 
be assumed to be 1:1. Thus, the ECN/αCD 1:1 complex dimers, tetramers and 382 
octamers can pass through semipermeable membranes of MWCO 3500, 6-8000 and 383 
12-14000 Da, respectively. γCD has higher MW and hence, the 1:1 ECN/γCD 384 
complex monomers, trimers and hexamers able to permeate these membranes, 385 
respectively. Figure 5 displays the flux and the Papp of ECN from ECN saturated 386 
aqueous CD solutions at various pH. As expected, both ECN permeation flux and 387 
Papp increased with increasing membrane MWCO. Also, the aggregate formation and 388 
their size increase with increasing CD concentration. The ECN flux from aqueous 389 
ECN saturated αCD solutions was higher in all cases than from comparable γCD 390 
solutions due to the higher ECN Cd in the αCD complexing medium. In case of ECN 391 
in saturated aqueous αCD solutions, the flux of ECN from ECN saturated αCD 392 
solutions did not increase proportionally with increasing αCD concentrations as 393 
would be expected from the observed A-type phase solubility profile. This shows that 394 
at higher αCD concentrations the solubilized ECN was partly present in soluble 395 
aggregates that could not permeate the membrane.  The ratio of the flux of ECN 396 
permeated through the incremental MWCO values (i.e., 6-8 kDa/3.5 kDa and 12-14 397 
kDa/3.5 kDa) are shown in Table 5. The fraction of small ECN/CD complex 398 
aggregates (i.e., tetramers to dimers and trimers to monomers in case of αCD and 399 
17 
 
γCD, respectively) increased with increasing CD concentrations. At pH 7.5 the small 400 
aggregates were predominant. Especially, the highest fraction of small aggregates 401 
(3-times higher) was observed in 10% αCD solution saturated with ECN (Table 5). In 402 
other words, the decreased ability to form ECN/CD complex aggregates at low pH 403 
(i.e. pH 3 and 5) was most probably due to the repulsion force between positively 404 
charged protonated ECN. This result was confirmed by the DLS data. In all cases, 405 
formation of ECN/γCD complex aggregates was less than in the case of αCD. 406 
Normally, in aqueous solutions γCD tends to self-aggregate at high γCD 407 
concentrations (Jansook et al., 2010b; Saokham and Loftsson, 2017). This 408 
phenomenon may hamper formation of ECN/γCD complexes and solubilization of 409 
ECN through formation of water-soluble complex aggregates. Thus, the saturated 410 
aqueous solutions containing complexes aggregates of ECN/αCD were selected to 411 
evaluate the antifungal activity. 412 
 413 
3.7 Antifungal susceptibility test 414 
The MICs and MFCs of ECN in saturated aqueous αCD solutions at pH 3 and 415 
5 against C. albicans, A. flavus and F. solani were obtained by broth microdilution 416 
technique (Table 6). ECN solubilized in aqueous αCD solutions had MIC and MFC 417 
ranging between 5-45 μg/ml and 0.7-11 μg/ml against C. albicans and filamentous 418 
fungi i.e., A. flavus and F. solani, respectively. Aqueous 10% w/v αCD solution 419 
saturated with ECN inhibited the growth of tested pathogenic fungi at the same ECN 420 
concentration or less than solutions without αCD. ECN/αCD solutions at pH 3 and 5 421 
did not display significantly different antimycolytic activity. In comparison to the 422 
uncomplexed ECN, the ECN/αCD inclusion complex showed higher fungicidal 423 
activity especially against A. flavus (MFC 0.7 μg/ml) followed by F. solani (MFC 11.0 424 
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μg/ml) while the CD complex did not enhance the antifungal activity of ECN against 425 
C. albicans (MFC ~44 μg/ml). The effect of pH on in vitro susceptibility of C. glabrata 426 
and C. albicans was investigated by Danby et al. (2012). It was found that C. 427 
albicans strains had reduced susceptibility to azole antifungal agents at pH 4. 428 
However, the exact mechanism of the pH induced reduction of the antifungal activity 429 
has not been established.  430 
Schär et al. (1976) reported that ECN was more active against filamentous 431 
fungi such as Aspergillus and Rhizopus spp. The results indicated that the CD 432 
complexation could improve antifungal activity in terms of both MIC and MFC to 433 
filamentous fungi. Gao et al. (2019) summarized that the inclusion complex of CD 434 
and chlorothalonil had better fungicidal activity than original chlorothalonil. Thus, 435 
ECN/αCD complex is a potential therapeutic alternative that can be further 436 
developed to pharmaceutical preparation for the treatment of infectious diseases 437 
(Díaz-Tomé et al., 2018; Jacobsen et al., 1999). 438 
In general, the ECN concentration must exceed the MIC in the epidermis and 439 
as deep as the middle region of the dermis for dermatophytes. Due to their size and 440 
hydrophilicity, CDs are not able to penetrate biological membranes. CDs enhance 441 
topical drug delivery by increasing the drug availability at the barrier surface and can 442 
only enhance topical drug delivery in the presence of water (Loftsson and Masson, 443 
2001). In addition, the CD complex aggregates may hamper the drug permeability 444 
through the lipophilic membrane. To overcome the difficulties, ECN/CD can be 445 
incorporated into hydrogel contained water-rich structure or lipid nanoparticles; for 446 





4. Conclusions 450 
The very low aqueous solubility of ECN is the main obstacle in ECN product 451 
development. CD complexation with pH adjustments can improve the ECN solubility. 452 
ECN has relatively high affinity to the αCD cavity, especially in acidic solutions. αCD 453 
can enhance the ECN solubility in aqueous solutions and increase the thermal 454 
stability of ECN. γCD cavity is too large to give a good fit with ENC molecule and 455 
γCD and its complexes have higher tendency to self-associate to form aggregates 456 
that limits the ECN solubility. The enhanced ECN solubility might be due to CD 457 
complex aggregates formation which was observed by DLS and permeation studies. 458 
At pH 3 and 5 the ECN saturated aqueous αCD solutions had antifungal activity 459 
against the tested filamentous fungi. The results show that αCD complexation can 460 
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Table 1 Econazole content in aqueous solution with and without 5% w/v CD at 
different pH after zero to three cycles of autoclaving.a 
Sample ECN content (mg/ml) (Mean ± S.D.) 
 0 cycle 1 cycle 2 cycles 3 cycles 
No CD 
pH 3 0.402 ± 0.039 0.395 ± 0.039 0.396 ± 0.039 0.402 ± 0.042 
pH 5 0.160 ± 0.034 0.159 ± 0.046 0.136 ± 0.041 0.127 ± 0.042 
pH 7.5 -b -b -b -b 
5% w/v αCD 
pH 3 2.824 ± 0.120 2.933 ± 0.108 3.019 ± 0.064 3.000 ± 0.057 
pH 5 2.072 ± 0.080 2.036 ± 0.099 2.101 ± 0.056 2.099 ± 0.063 
pH 7.5 0.342 ± 0.009 c 0.325 ± 0.016 0.285 ± 0.035 0.279 ± 0.024 c 
5% w/v γCD 
pH 3 0.759 ± 0.021 0.761 ± 0.015 0.761 ± 0.033 0.772 ± 0.022 
pH 5 0.108 ± 0.008 0.106 ± 0.011 0.094 ± 0.064 0.089 ± 0.018 
pH 7.5 -b -b -b -b 
  aEach cycle consisted of heating to 121oC for 20 minutes. 
 bCould not determined (ECN conc. below LOQ). 
cP < 0.05. P < 0.05 was considered statistically significant between 3 cycles of 



















Table 2 The values of the apparent stability constants (i.e. K1:1 and K1:2) and the 
complexation efficiency (CE) of econazole/CD complexes in aqueous CD solutions 
with different pH at 22-23qC. 
 
Cyclodextrin pH S0  
(mM) 




CE Molar ratio 
αCD 3 1.05 AL 354.5 - 0.371 1:4 
 5 1.13x10-1 AL 2597.5 - 0.293 1:5 
 7.5 1.11x10-3 Ap 870.2 15.0 0.041 a 1:25 
γCD  3 1.05 Bs 246.7 - 0.258 a 1:5 
 5 1.13x10-1 Bs 1032.8 - 0.117 a 1:10 
 7.5 1.11x10-3 - b - b - b - b - b 
aObtained from the initial linear part of the phase-solubility diagram. 























Table 3. The 1H-chemical shifts of αCD or γCD alone and in the presence of 
econazole 
 
Protons CD ECN/CD Δδ* 
αCD    
H1 4.984 4.955 - 0.029 
H2 3.563 3.546 - 0.017 
H3 3.895 3.719 - 0.176 
H4 3.515 3.496 - 0.019 
H5 3.794 3.822 +0.028 
γCD    
H1 5.043 5.016 - 0.027 
H2 3.572 3.581 +0.009 
H3 3.835 3.771 - 0.064 
H4 3.491 3.504 +0.013 
H5 3.781 3.745 - 0.027 
        'δ* = δcomplex- δfree 



















Table 4. The DLS results of aqueous solution of ECN saturated in aqueous CD 
solutions at 25oC±0.5oC. Data reported as the means of three determinations, the 
hydrodynamic diameter (d), intensity area (%A) and, mass distribution (%M). The 
samples were filtered through 0.45 Pm membrane filter prior to analysis.  
 
Sample pH Peak summary 
d (nm) %A %M 
αCD(%w/v)     
1 3 1.07±0.04 100 100 
5  1.07±0.08 100 100 
10  1.05±0.12 79.93 97.78 
  2.35±0.97 20.07 2.22 
1 5 1.00±0.01 100 100 
5  0.97±0.01 100 95.99 
  1.64±1.43 78.47 4.01 
  334.03±6.13 15.77 - 
10  0.97±0.02 81.00 98.37 
  2.04±0.41 12.40 1.63 
  464.37±157.83 6.60 - 
1 7.5 1.05±0.01 100 100 
5  0.96±0.02 67.37 100 
  239.70±47.23 3.20 - 
  518.33±87.65 29.43 - 
10  0.96±0.01 51.20 96.14 
  1.83±0.79 13.57 3.66 
  4.83±1.49 13.67 0.20 
  303.90±55.18 21.57 - 
γCD (%w/v)     
1 3 1.28±0.07 100 100 
5  1.15±0.11 100 100 
10  1.00±0.03 97.03 100 
  390.93±111.97 2.97 - 
1 5 1.01±0.02 98.53 99.66 
  1.66±0.63 1.48 0.34 
5  1.15±0.06 91.97 98.64 
  2.13±0.38 8.03 1.36 
10  1.20±0.02 47.71 95.38 
  2.24±0.67 14.97 4.62 






Table 5. The fraction of size population at different cyclodextrin solutions containing 
saturated econazole which pass through the various MWCO of semipermeable 
membranes. 
 
MWCO (kDa)   αCD conc. (%w/v) γCD conc. (%w/v) 
 1 5 10 1 5 10 
pH 3         
(6-8)/3.5 1.37 1.45 1.75 1.19 1.34 1.38 
(12-14)/3.5 1.86 2.90 2.61 1.47 1.62 1.93 
pH 5        
(6-8)/3.5 1.37 1.41 1.51 1.01 1.06 1.10 
(12-14)/3.5 1.55 2.56 2.64 0.53 0.16 0.28 
pH 7.5        
(6-8)/3.5 1.54 1.70 1.98 - - - 



















Table 6. In vitro activities of saturated aqueous ECN/αCD solutions in different pH 
against important medical fungi (Mean, n=3). 
 
Samples 
C. albicans A. flavus F. solani 
MIC MFC MIC MFC MIC MFC 
ECN 5.0 20.0 1.25 1.25 5.0 20.0 
ECN/αCD, pH 3 5.5 43.8 0.7* 0.7* 5.5 11.0* 
ECN/αCD, pH 5 5.7  45.5 0.7* 0.7* 5.7 11.0* 
a ECN: econazole nitrate; ECN/αCD: saturated ECN in aqueous solution  
containing 10% w/v αCD 
b MIC, MFC (Pg/ml); * more effective than ECN itself when half strength  
was given. 
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Fig. 1. The pH-solubility profiles of econazole in pure water and in aqueous 
solutions containing 5% w/v αCD or γCD at 22-23qC; pure water (○), 
αCD (□), γCD (●). 
 
Fig. 2.  The unionized and ionized form of econazole, pKa = 6.6. 
 
Fig. 3. Phase-solubility profiles of econazole in aqueous solutions containing 
αCD (a) or γCD (b) at different pH (22-23qC); pH 3 (○), pH 5 (●), pH 7.5 
(□). 
 
Fig. 4.  The theoretical and observed CD solubility in aqueous solution 
saturated with ECN at different pH. The theoretical CD concentrations 
means the amount of CD added to the aqueous media while the 
observed CD concentrations were derived from HPLC determination. 
Theoretical (----); observed (); pH 3 (○); pH 5 (●); pH 7.5 (□). 
 
Fig. 5.  Permeation flux and apparent permeability coefficient (Papp) of 
econazole saturated 1, 5 and 10% w/v CD solutions at different pH 
through semipermeable membranes of various molecular weight cut-off 
(MWCO). ECN flux against CD concentrations; αCD (a); γCD (b), ECN 
Papp against CD concentrations; αCD (c); γCD (d); MWCO 3500 Da (■); 





Fig. 1. The pH-solubility profiles of econazole in pure water and in aqueous solutions 






































    
 
Fig. 3. Phase-solubility profiles of econazole in aqueous solutions containing αCD (a) 
















                        
Fig. 4. The theoretical and observed CD solubility in aqueous solution saturated with 
ECN at different pH. The theoretical CD concentrations means the amount of CD 
added to the aqueous media while the observed CD concentrations were derived 


















Fig. 5. Permeation flux and apparent permeability coefficient (Papp) of econazole 
saturated 1, 5 and 10% w/v CD solutions at different pH through semipermeable 
membranes of various molecular weight cut-off (MWCO). ECN flux against CD 
concentrations; αCD (a); γCD (b), ECN Papp against CD concentrations; αCD (c); 
γCD (d); MWCO 3500 Da (■); MWCO 6-8,000 Da (□) MWCO 12-14,000 Da ( ). 
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